Congress Asset Management’s Royalty Pharma RPRX Stock Holding History

Congress Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$30.8M	Buy	+527,094	New	+$31.1M	0.2%	123

Other funds holding RPRX

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Kearns & Associates Palos Verdes Estates, California $218M AUM 16.36% 1-Year Est. Return

Miller Global Investments Dallas, Texas $124M AUM 25.7% 1-Year Est. Return

Wedmont Private Capital West Chester, Pennsylvania $4.18B AUM 18.65% 1-Year Est. Return

Legacy Wealth Asset Management Woodbury, Minnesota $456M AUM 31.62% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Ridgewood Investments Springfield, New Jersey $271M AUM

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Congress Asset Management's RPRX Position: Q3 2026 in Review

Congress Asset Management opened a new position in Royalty Pharma (RPRX) in Q3 2026: 527,094 shares worth $30.8M. The stake represents 0.2% of the portfolio and ranks #123 among its holdings.

21 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.

Congress Asset Management held 527,094 shares of Royalty Pharma worth $30.8M as of Q3 2026.
Royalty Pharma was a new Congress Asset Management position in Q3 2026.
Royalty Pharma made up 0.2% of Congress Asset Management's portfolio in Q3 2026, its #123 holding.
21 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.

Based on Congress Asset Management's 13F filing for Q3 2026, filed 6 Oct 2026.